GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BioAtla Inc.
BioAtla is a biotech company developing a new class of antibodies for targeted cancer therapy. Its stock price represents a venture bet on the success of its scientific platform. The stock price reflects high volatility and dependence on clinical trial data.
Share prices of companies in the market segment - General oncology therapy
BioAtla is an oncology company developing a new class of antibodies that are activated only in the tumor microenvironment, reducing side effects. We've categorized the company as a "General Oncology" company. The chart below shows how the market is evaluating innovative approaches to targeted therapy.
Broad Market Index - GURU.Markets
BioAtla is an oncology company developing a new class of antibodies that are activated only in the tumor microenvironment, reducing side effects. As a component of the GURU.Markets index, it represents the targeted therapy sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BCAB - Daily change in the company's share price BioAtla Inc.
For BioAtla, Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to news about the clinical trials of its targeted antibodies and is an important metric for assessing risk.
Daily change in the price of a set of shares in a market segment - General oncology therapy
BioAtla, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with BCAB's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
BioAtla is a biotech company developing "smart" drugs that are activated only within tumors. The company's shares are a bet on a scientific breakthrough. Their high, speculative volatility is part of the dynamics of the innovation sector, which influences the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BioAtla Inc.
BioAtla, Inc.'s annual performance is a story of developing a new generation of "smart" antibodies for cancer treatment. Its 12-month market capitalization is entirely dependent on clinical trial data. The success of its technology, which activates antibodies only in the tumor environment, could fundamentally improve the safety and efficacy of cancer therapy.
Annual dynamics of market capitalization of the market segment - General oncology therapy
BioAtla, Inc. is a biotech company developing a new class of targeted immunotherapy for cancer. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioAtla is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BioAtla Inc.
BioAtla is a clinical-stage oncology company developing conditionally active antibodies. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its lead programs are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
BioAtla is developing a new class of antibodies for targeted cancer therapy. This oncology segment is one of the most competitive and fastest-growing in biotech. The chart below reflects the overall investor sentiment toward innovative oncology platforms and their belief in the emergence of more effective and safer treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioAtla is a biotech company developing "smart" antibodies that are activated only within tumors. This is a cutting-edge scientific concept. The company's stock price is entirely dependent on whether this technology proves effective in clinical trials and is not tied to market cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BioAtla Inc.
BioAtla is a biotech company developing an innovative class of tumor-activated oncology drugs. Its weekly stock price has been highly volatile, as investors are keenly aware of any clinical trial data that could confirm or refute its unique scientific approach.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
BioAtla is a biotech company developing an innovative class of tumor-activated oncology drugs. Its weekly stock price has been highly volatile, as investors are keenly aware of any clinical trial data that could confirm or refute its unique scientific approach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BioAtla, a biotech company, lives in a world of its own. Its performance is driven by clinical trial data. A chart comparing it to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
BCAB - Market capitalization of the company BioAtla Inc.
BioAtla's market capitalization chart tells the story of the development of a new generation of "smart" antibodies for cancer treatment that are activated only within the tumor environment. Its volatile chart reflects investor hopes for this technology, which promises to be more effective and less toxic. It's a visualization of a risky bet on a breakthrough in oncology.
BCAB - Share of the company's market capitalization BioAtla Inc. within the market segment - General oncology therapy
BioAtla is a clinical-stage biopharmaceutical company developing a new class of antibodies (CAB) that are activated only in tumors. Its share of its segment's market capitalization reflects the breakthrough potential of this technology. The chart below shows the valuation volatility dependent on clinical trial results.
Market capitalization of the market segment - General oncology therapy
BioAtla is developing a new class of antibodies (CAB) that are activated only in the tumor microenvironment, reducing side effects. The chart below shows the overall market capitalization of the oncology sector. It illustrates cutting-edge scientific approaches aimed at creating smarter and safer cancer drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the development of "smart" antibodies against cancer. BioAtla creates drugs that are activated only within the tumor, reducing side effects. Its volatile line on the graph reflects the progress of this promising technology in clinical trials.
Book value capitalization of the company, segment and market as a whole
BCAB - Book value capitalization of the company BioAtla Inc.
BioAtla's capital is its scientific platform for creating conditionally active antibodies that target cancer cells while minimizing damage to healthy tissue. This is cutting-edge scientific capital. The chart shows how the biotech company accumulates and spends significant funds on clinical trials of its innovative approach to cancer therapy.
BCAB - Share of the company's book capitalization BioAtla Inc. within the market segment - General oncology therapy
BioAtla is a biotech company developing "smart" antibodies that activate only within tumors. Its assets are laboratories and patents. The chart shows the minimal share of physical assets, as its value lies in its unique scientific platform.
Market segment balance sheet capitalization - General oncology therapy
Developing antibodies for cancer treatment, as the BCap_Seg chart for biotech shows, is a science-intensive endeavor. BioAtla operates in this environment. Its capital is invested in the scientific platform and clinical trials, not in building giant factories.
Book value of all companies included in the broad market index - GURU.Markets
BioAtla's balance sheet consists of capital and cutting-edge laboratories for the development of a new class of antibodies that are activated only in cancer tumors. Its value provides the financial foundation for the creation of "smart" physical drugs that could revolutionize targeted therapy.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BioAtla Inc.
BioAtla is developing a new class of oncology antibodies that are activated only in the tumor environment. This is cutting-edge science. The company's book value is negligible compared to the potential of its platform. The MvsBCap chart is a bet on the success of this innovative technology. It will reflect clinical trial data, not financial performance.
Market to book capitalization ratio in a market segment - General oncology therapy
BioAtla is a biotech company developing a new class of targeted oncology drugs. Its value is entirely dependent on the success of its scientific platform. The chart reflects investor appreciation for its innovative approach to creating safer cancer drugs.
Market to book capitalization ratio for the market as a whole
BioAtla is developing a new class of antibodies (CAB) that are activated only in the tumor environment, increasing their safety. This is a breakthrough technology in oncology. The company's market valuation reflects investors' bet on the success of this platform. The chart shows the premium the market places on fundamental innovations in cancer treatment.
Debts of the company, segment and market as a whole
BCAB - Company debts BioAtla Inc.
BioAtla, a biotech company developing a new class of "smart" antibodies for cancer treatment, is dedicating all of its raised capital to clinical trials of its candidate drugs. This cutting-edge technology requires significant investment. This chart shows how the company is funding its research, which could change the face of targeted cancer therapy.
Market segment debts - General oncology therapy
BioAtla, Inc. is a clinical-stage biotechnology company developing a new class of targeted oncology drugs (CAB antibodies). Funding breakthrough, yet risky, research is its primary focus. This chart illustrates how BioAtla is building its financial strategy to bring its unique technology to patients.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BioAtla Inc.
BioAtla is developing a new class of antibodies for targeted cancer therapy. This chart shows its reliance on external funding to conduct expensive clinical trials. As with many biotechs, high debt is a prerequisite for innovation but creates existential risk if key research fails.
Market segment debt to market segment book capitalization - General oncology therapy
BioAtla is developing a new class of oncology drugs—antibodies that are conditionally active in tumors. The chart shows the debt burden in the biotech sector. It allows one to evaluate how the company finances its innovative and risky scientific platform compared to other companies working to create safer and more effective cancer treatments.
Debt to book value of all companies in the market
BioAtla, Inc. is a biopharmaceutical company developing a new class of highly specific anti-cancer antibodies. The total debt burden shown in the chart forms the investment backdrop. For biotech companies in clinical trials, access to capital to continue development is a matter of survival and is directly dependent on the health of the market.
P/E of the company, segment and market as a whole
P/E - BioAtla Inc.
For BioAtla, Inc., a biopharmaceutical company developing drugs that are activated only within tumors, this chart shows the valuation of its unique technology. High values reflect investors' hopes for safer and more effective cancer treatments with fewer side effects.
P/E of the market segment - General oncology therapy
This chart shows the average P/E for the biotech sector, where BioAtla develops smart drugs. The industry's very high valuation reflects hopes for breakthroughs in oncology. The chart illustrates this general backdrop against which BioAtla's unique technology for targeted drug activation is evaluated.
P/E of the market as a whole
BioAtla is developing a new generation of antibodies that are activated only in the tumor microenvironment. This approach should improve treatment efficacy and reduce side effects. This chart illustrates risk appetite in biotech. It helps understand whether the market believes in the breakthrough potential of BioAtla's platform and how its valuation responds to clinical trial data compared to other oncology companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BioAtla Inc.
BioAtla is a biopharmaceutical company developing a new class of oncology drugs—conditionally active antibodies that are activated only in the tumor environment. This increases their safety. This graph demonstrates analysts' confidence that this innovative technology will prove effective in clinical trials.
%20P%2FE%20BioAtla%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BioAtla-Inc.&v=1772528752759 "Chart of the company's future (projected) P/E BioAtla Inc.")
Future (projected) P/E of the market segment - General oncology therapy
BioAtla is developing a new class of highly specific oncology drugs that are activated only in the tumor microenvironment. This graph depicts its future profitability expectations, allowing us to assess how highly the market values its innovative approach to improving treatment efficacy and reducing side effects.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772528752788 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
BioAtla is a biopharmaceutical company developing a new class of targeted cancer therapies. Its valuation is based on its scientific potential. This chart, reflecting the market's risk appetite, is critical for BioAtla. During periods of optimism, investors are more inclined to fund companies with breakthrough but not yet fully proven technologies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772528752898 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BioAtla Inc.
BioAtla, Inc. is a biotech company developing a new class of antibodies that are activated only within tumors (CAB therapy). This allows for more precise cancer targeting. Its funding comes from investments in clinical trials. This chart shows how much is being invested in this breakthrough technology, which promises to improve the effectiveness and safety of cancer treatment.
Profit of companies in the market segment - General oncology therapy
BioAtla is a biopharmaceutical company developing a new class of "conditionally active" antibodies for cancer treatment. These antibodies are activated only in the tumor microenvironment, reducing side effects. This graph reflects the high potential in the targeted oncology sector, where improving therapy selectivity is key to creating safer and more effective drugs.
Overall market profit
BioAtla is developing a new class of oncology antibodies that are activated only in tumors. This is a breakthrough, but risky technology. The overall investment climate, which this graph indirectly reflects, is critical for the company, as it determines the availability of capital for costly clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BioAtla Inc.
BioAtla is a biopharmaceutical company developing a new class of "smart" anti-cancer antibodies that activate only within tumors, reducing side effects. This chart summarizes analyst forecasts, reflecting the success of this innovative technology in clinical trials and its future commercial potential.
%20profit%20of%20the%20company%20BioAtla%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BioAtla-Inc.&v=1772528753347 "Graph of future (projected) profit of the company BioAtla Inc.")
Future (predicted) profit of companies in the market segment - General oncology therapy
BioAtla, Inc. is a biotech company developing a new class of "conditionally active" antibodies for cancer treatment. These drugs are activated only in the tumor microenvironment, potentially reducing side effects on healthy tissue. This chart shows profitability projections for the biotech sector, reflecting hopes for safer and more effective immunotherapies.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772528753377 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
BioAtla is a biotech company developing a new class of targeted cancer therapies. Its development requires a constant influx of capital to conduct clinical trials. This schedule, reflecting overall market sentiment, influences investor willingness to finance long-term, high-risk biotech projects, which will determine BioAtla's future.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772528753401 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BioAtla Inc.
BioAtla is developing a new class of antibodies for cancer treatment. This chart is a measure of hope. For a biotech company, a high market value with minimal sales reflects the enormous potential of its scientific platform and investors' faith in the future success of its drugs.
P/S market segment - General oncology therapy
BioAtla, Inc. is a biopharmaceutical company developing a new class of targeted anti-cancer drugs that are activated only within the tumor environment. This chart reflects the average revenue estimate in the biotech sector. It allows one to estimate the premium investors are placing on the potential of BioAtla's innovative technology to improve the efficacy and safety of cancer treatment.
P/S of the market as a whole
BioAtla is developing a new generation of targeted cancer immunotherapy that is activated only in the tumor microenvironment, potentially reducing side effects. Their value lies in this innovative platform. This chart provides a general measure of revenue valuation, which can be used to assess how highly investors value scientific breakthroughs in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BioAtla Inc.
BioAtla is developing a new class of anti-cancer antibodies that are activated only in the tumor microenvironment, potentially reducing side effects. This chart reflects investors' confidence in this innovative technology. The company's valuation is based entirely on future revenues that could accrue if its clinical development is successful.
%20P%2FS%20BioAtla%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BioAtla-Inc.&v=1772528753510 "The graph of the company's future (projected) P/S BioAtla Inc.")
Future (projected) P/S of the market segment - General oncology therapy
BioAtla is a clinical-stage biopharmaceutical company developing a new class of highly specific anti-cancer antibodies that are activated only in the tumor microenvironment. This approach may reduce side effects. This chart shows how the market values its innovative platform compared to the oncology sector.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772528753523 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
BioAtla is a biotech company developing a new class of anti-cancer antibodies that are activated only in tumors. This chart, reflecting investor appetite for breakthrough scientific platforms, is important for BioAtla. Market optimism facilitates raising the capital needed to conduct clinical trials of this innovative and promising technology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772528753560 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BioAtla Inc.
BioAtla is a clinical-stage biopharmaceutical company developing a new class of highly specific antibodies for cancer treatment (CAB). This chart reflects revenue from strategic partnerships and licensing agreements. It illustrates the financial support for this innovative platform, which is designed to target only cancer cells while minimizing damage to healthy tissue.
Sales of companies in the market segment - General oncology therapy
BioAtla, Inc. is a biotechnology company developing a new class of highly specific anti-cancer antibodies that are activated only in the tumor microenvironment. Its activities are segmented by various development programs for these innovative drugs. This chart depicts the financial flows associated with one of its lead candidates, showing its progress.
Overall market sales
BioAtla, Inc. is a biotechnology company developing a new class of antibodies that are activated only within tumors (CAB). This approach has the potential to significantly reduce the side effects of chemotherapy. The company's success depends on the results of clinical trials and could lead to a breakthrough in cancer treatment, demonstrating how science creates new economic value.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BioAtla Inc.
BioAtla is a clinical-stage biopharmaceutical company developing a new class of highly specific antibodies that are activated only in the tumor microenvironment (CAB antibodies). Future sales projections are based on the belief that this technology will enable the creation of safer and more effective cancer treatments with fewer side effects.
%20sales%20of%20the%20company%20BioAtla%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BioAtla-Inc.&v=1772528753624 "Schedule of future (projected) sales of the company BioAtla Inc.")
Future (projected) sales of companies in the market segment - General oncology therapy
BioAtla, Inc. is developing a new class of targeted anticancer drugs that are activated only in the tumor microenvironment. This graph illustrates expectations for the entire oncology sector. It reflects analysts' predictions regarding breakthroughs in safer and more effective treatments, which are key to the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772528753642 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
BioAtla, a biotech company developing a new class of targeted cancer therapies, is a company whose funding and valuation depend on investor appetite for risky but promising scientific developments. This chart of overall sales forecasts reflects the overall market sentiment, which impacts the availability of capital for biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772528753651 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BioAtla Inc.
BioAtla, Inc. is a clinical-stage biopharmaceutical company developing a new class of highly specific antibodies for cancer treatment that are activated only in the tumor environment. This chart reflects its financial trajectory, where significant investments in breakthrough science are the foundation for the creation of future, safer cancer treatments.
Market segment marginality - General oncology therapy
BioAtla is developing a new class of antibodies for targeted cancer therapy that are activated only within the tumor environment. This approach aims to improve R&D efficiency by reducing toxicity. The graph shows how their scientific strategy optimizes costs compared to other oncology companies.
Market marginality as a whole
BioAtla, Inc. is a biotech company developing a new class of antibodies that are activated only in the tumor microenvironment. This allows for increased efficacy and reduced side effects. This graph shows the profitability of existing businesses, while BCAB's value is determined by the potential of its breakthrough technology for cancer treatment.
Employees in the company, segment and market as a whole
Number of employees in the company BioAtla Inc.
BioAtla is developing a new generation of "smart" anti-cancer antibodies that are activated only within tumors. This graph shows its team of highly qualified scientists. The growth of this intellectual capital is directly linked to the progress of its innovative platform and the advancement of candidate drugs through clinical trials.
Share of the company's employees BioAtla Inc. within the market segment - General oncology therapy
BioAtla is developing a new class of targeted anti-cancer drugs that are activated only within the tumor environment. This innovative technology requires a team of world-class scientists. This chart illustrates the scale of its workforce in the competitive field of precision oncology, which promises safer treatments.
Number of employees in the market segment - General oncology therapy
BioAtla, Inc. is a biopharmaceutical company developing a new class of antibodies that are activated only in the tumor microenvironment. This chart reflects the oncology sector. The growing number of scientists working in the field of targeted therapy reflects the search for safer and more effective cancer treatments, which aligns with BioAtla's innovative approach.
Number of employees in the market as a whole
BioAtla is developing a new class of antibodies for targeted cancer therapy. For such an innovative biopharmaceutical company, hiring trends are determined not by the overall labor market situation, but by research progress. The success of Phase III trials is more important than this graph.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BioAtla Inc. (BCAB)
BioAtla, Inc. is a biopharmaceutical company developing a new class of antibodies for cancer treatment. This chart shows a very high market capitalization per employee, which is typical for biotech. The market value reflects not current sales, but rather investors' faith in the breakthrough potential of a scientific platform created by a small team of scientists.
%20of%20the%20company%20BioAtla%20Inc.%20(BCAB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BioAtla-Inc.-BCAB&v=1772528754188 "Chart of market capitalization per employee (in thousands of dollars) of the company BioAtla Inc. (BCAB)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
BioAtla, Inc. is a biopharmaceutical company developing a new class of targeted therapies for cancer. In oncology, cost per employee is a measure of investor valuation of the scientific platform and potential of clinical candidates. This chart shows how highly the market values their innovative approach to creating safer and more effective drugs.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772528754201 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
BioAtla, Inc. is a biotech company developing a new class of antibodies that are activated only in the tumor microenvironment. This allows for cancer treatment with greater precision and fewer side effects. The chart shows the high premium the market commands for this breakthrough scientific platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772528754286 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BioAtla Inc. (BCAB)
BioAtla is a clinical-stage biopharmaceutical company developing a new generation of "smart" antibodies (CABs) that activate only within tumors, reducing side effects. This is cutting-edge oncology. This negative graph shows how much capital is being burned per scientist working on this complex R&D platform in the hopes of creating safer and more effective cancer treatments.
%20Chart%20BioAtla%20Inc.%20(BCAB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BioAtla-Inc.-BCAB&v=1772528754458 "Company Profit Per Employee (in thousands of dollars) Chart BioAtla Inc. (BCAB)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
BioAtla is a biopharmaceutical company developing a new class of antibodies that are activated only in cancer tumors. Their technology requires the highest scientific expertise. This chart shows how productive their elite team of scientists is in creating value, allowing them to compare with other players in innovative oncology.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772528754526 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
BioAtla (BCAB) is a biotech company developing targeted (conditionally active) antibodies for cancer treatment. It is a clinical-stage R&D company. Negative profit per employee is the norm. The chart shows the "cost" of the team of scientists working on this complex technological platform, which does not yet generate revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772528754633 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BioAtla Inc. (BCAB)
BioAtla is a biotech company developing a new class of targeted oncology drugs. While in the clinical stage, its revenue may be minimal. This timeline will show whether its scientific platform can lead to the creation of commercially successful drugs with high yields.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BioAtla-Inc.-BCAB&v=1772528754731 "Sales chart per company employee BioAtla Inc. (BCAB)")
Sales per employee in the market segment - General oncology therapy
BioAtla is a biotech company developing conditionally active antibodies (CABs) for cancer treatment. These drugs are activated only within the tumor, reducing toxicity. This chart compares revenue per employee (R&D) to the industry average, reflecting the productivity and value of their unique scientific platform.
Sales per employee for the market as a whole
BioAtla (BCAB) is a biotech company developing a new generation of smart antibodies (CAB) for cancer treatment that are activated only within the tumor. This is an R&D platform. Being in the clinical stage, the company has no sales revenue. This graph will show $0 or partnership revenue, reflecting the team's focus on research.
Short shares by company, segment and market as a whole
Shares shorted by company BioAtla Inc. (BCAB)
BioAtla (BCAB) is an oncology company developing "conditionally active" antibodies. Their drugs are designed to be activated only within the tumor, reducing side effects. This is promising but complex science. This chart shows the number of skeptics who doubt this technology will prove effective and safe in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BioAtla-Inc.-BCAB&v=1772528754846 "Short Shares Chart for the Company BioAtla Inc. (BCAB)")
Shares shorted by market segment - General oncology therapy
BioAtla is a biotech company developing smart antibodies (CABs) that activate only within tumors, which should reduce the side effects of chemotherapy. This chart shows the odds against the oncology biotech sector, reflecting the high skepticism among investors that this complex technology will prove effective.
Shares shorted by the overall market
BioAtla (BCAB) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing BCAB won't be able to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BioAtla Inc. (BCAB)
BioAtla, Inc. is an oncology company developing "conditionally active" antibodies that attack cancer only within the tumor, reducing side effects. This oscillator measures the excitement around their platform, showing "overheated" (above 70) on positive trial data or "oversold" (below 30) on delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BioAtla-Inc.-BCAB&v=1772528754945 "RSI 14 indicator chart for the company's stock BioAtla Inc. (BCAB)")
RSI 14 Market Segment - General oncology therapy
BioAtla is a biotech company developing conditionally active antibodies (CABs) for cancer treatment. These drugs are designed to be activated only in the tumor microenvironment, which reduces toxicity. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire segment is overheated.
RSI 14 for the overall market
For BioAtla, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BCAB (BioAtla Inc.)
BioAtla is a biotech company developing conditionally active antibodies (CABs) for the treatment of cancer that are activated only within the tumor. This chart shows the average target price. Analysts' estimates are based on clinical data demonstrating the safety and efficacy of this innovative platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BCAB-BioAtla-Inc.&v=1772528755001 "A chart showing analyst consensus forecasts for the expected stock price. BCAB (BioAtla Inc.)")
The difference between the consensus estimate and the actual stock price BCAB (BioAtla Inc.)
BioAtla is a biotech company developing conditionally active antibodies (CABs) for cancer treatment. Their drugs are activated only within the tumor, reducing side effects. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their faith in this "smart" oncology platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BCAB-BioAtla-Inc.&v=1772528755005 "A chart showing the difference between the consensus forecast and the actual stock price. BCAB (BioAtla Inc.)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
BioAtla is a biotech company developing "smart" antibodies (CABs) that are activated only within cancer tumors, sparing healthy tissue. This chart shows the overall expectations for the general oncology sector. It reflects whether experts believe in a breakthrough in "conditionally activated" cancer therapy.
Analysts' consensus forecast for the overall market share price
BioAtla is a biotech company developing smart antibodies (CABs) for cancer treatment that are programmed to activate only in the tumor microenvironment. This graph shows the overall market "risk appetite." For BioAtla, a clinical-stage company with an innovative platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BioAtla Inc.
BioAtla is smart oncology. They are developing conditionally active antibodies (CABs), which lie dormant in healthy tissue but are activated only in the acidic environment of tumors, which should reduce side effects. This graph is a clear indicator of faith in their R&D. It reflects their progress in clinical trials and the market's confidence in their innovative CAB platform.
AKIMA Market Segment Index - General oncology therapy
BioAtla (BCAB) is an oncology company developing conditionally active (CAB) antibodies. These drugs are designed to be activated only in the tumor microenvironment, sparing healthy tissue. The chart shows the average index for the segment, helping investors assess how this innovative targeted therapy platform compares to the average risk in oncology.
The AKIM Index for the overall market
BioAtla is a biotech company developing conditionally active biologics (CABs) for cancer treatment. These drugs are activated only in the acidic environment of tumors. This chart, which reflects the market average, provides a macro-scale backdrop. It helps assess how this innovative platform, which reduces treatment toxicity, compares to overall economic trends.
